Vitenskapelig artikkel

• B.G. Nedrebø; U.-B. Ericsson; Ottar Nygård et al. (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. (ekstern lenke)
• A Decensi; S Gandini; A Guerrieri-Gonzaga et al. (1999). Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction. (ekstern lenke)
• Monika Christensen; Ellen M Apalset; Yngve Nordbø et al. (2013). 1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism apa1 influence bone mineral density in primary hyperparathyroidism. (ekstern lenke)
• Per Eystein Lønning; Ernst Asbjørn Lien (1994). Pharmacokinetics of anti-endocrine agents. (ekstern lenke)
• Simon Steinar Hustad; Bjørn Gunnar Nedrebø; Per Magne Ueland et al. (2004). Phenotypic expression of the methylenetetrahydrofolate reductase 677C->T polymorphism and flavine cofactor availability in thyroid dysfunction. (ekstern lenke)
• Thomas Helland; Nina Henne; Ersilia Bifulco et al. (2017). Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. (ekstern lenke)
• Gun Birgitta Anker; Per Eystein Lønning; Asbjørn Aakvaag et al. (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. (ekstern lenke)
• Per Eystein Lønning; K. Hall; A. Aakvaag et al. (1992). Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. (ekstern lenke)
• Bjørn G Nedrebø; Ottar Nygård; Per Magne Ueland et al. (2001). Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment. (ekstern lenke)
• Ernst Asbjørn Lien; Dag Clement Johannessen; A. Aakvaag et al. (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. (ekstern lenke)
• Ernst Asbjørn Lien; D. C. Johannesen; A. Aakvaag et al. (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. (ekstern lenke)
• Kari Britt Hagen; Turid Aas; Kirsten Lode et al. (2014). Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale. (ekstern lenke)
• Jan Schjøtt; Jennifer Gjerde; Elton Richard Kisanga et al. (2006). Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. (ekstern lenke)
• Monika Christensen; Ingvild Sveinsgjerd Fenne; Yngve Nordbø et al. (2015). Novel inflammatory biomarkers in primary hyperparathyroidism. (ekstern lenke)
• Per Eystein Lønning; Svein Inge Helle; Dag Clement Johannesen et al. (1995). Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. (ekstern lenke)
• Ernst Asbjørn Lien; Gun Birgitta Anker; Per Eystein Lønning et al. (1990). Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. (ekstern lenke)
• Paal Methlie; Eystein Sverre Husebye; Simon Steinar Hustad et al. (2011). Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease. (ekstern lenke)
• Tuyen Hoang; Ingvild Sveinsgjerd Fenne; Andre Greger Madsen et al. (2013). cAMP response element-binding protein interacts with and stimulates the proteasomal degradation of the nuclear receptor coactivator GRIP1. (ekstern lenke)
• B.G. Nedrebø; U.-B. Ericsson; Ottar Nygård et al. (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. (ekstern lenke)
• B.G. Nedrebø; U.-B. Ericsson; Ottar Nygård et al. (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. (ekstern lenke)
• Monika Christensen; Eva Kristine Ringdal Pedersen; Yngve Nordbø et al. (2012). Vitamin B6 status and interferon-γ-mediated immune activation in primary hyperparathyroidism. (ekstern lenke)
• Elham Karimian; Andrei S Chagin; Jennifer Fernandez Gjerde et al. (2008). Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. (ekstern lenke)
• Ernst Asbjørn Lien; Dag Clement Johannessen; A. Aakvaag et al. (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. (ekstern lenke)
• B Bonanni; H Johansson; S Gandini et al. (2001). Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. (ekstern lenke)
• Per Eystein Lønning; K. Hall; A. Aakvaag et al. (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. (ekstern lenke)
• Ingvild Sveinsgjerd Fenne; Tuyen Hoang; Marianne Hauglid et al. (2008). Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase. (ekstern lenke)
• Thomas Helland; Jennifer Gjerde; Simon N Dankel et al. (2015). The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells. (ekstern lenke)
• Per Eystein Lønning; Dag Clement Johannessen; Ernst Asbjørn Lien et al. (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. (ekstern lenke)
• Pål Ivar Holm; Per Magne Ueland; Gry Kvalheim et al. (2003). Determination of choline, betaine, and dimethylglycine in plasma by a high-troughput metod based on normal-phase chromatography-tandem mass spectrometry. (ekstern lenke)
• Gun Birgitta Anker; Helga Refsum; Per Magne Ueland et al. (1999). Influence of aromatase inhibitors on plasma total homocysteine levels in postmenopausal breast cancer patients. (ekstern lenke)
• Timothy L Lash; Ernst Asbjørn Lien; Henrik Toft Sørensen et al. (2009). Genotype-guided tamoxifen therapy: time to pause for reflection?. (ekstern lenke)
• Thomas Helland; Kari Britt Hagen; Martha Eimstad Haugstøyl et al. (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. (ekstern lenke)
• Gun Birgitta Anker; Per Eystein Lønning; Asbjørn Aakvaag et al. (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. (ekstern lenke)
• Gun Birgitta Anker; Per Eystein Lønning; Per Magne Ueland et al. (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. (ekstern lenke)
• Jennifer Fernandez Gjerde; Marianne Hauglid; M Hauglid et al. (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. (ekstern lenke)
• Ernst Asbjørn Lien; E. Solheim; P. M. Ueland (1991). Distribution of tamoxifen and its metabolites in tissues of rat and man during steady state treatment. (ekstern lenke)
• Ernst Asbjørn Lien; Knut Wester; Per Eystein Lønning et al. (1991). Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. (ekstern lenke)
• B.G. Nedrebø; U.-B. Ericsson; Ottar Nygård et al. (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. (ekstern lenke)
• Per Eystein Lønning; K. Hall; A. Aakvaag et al. (1992). Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. (ekstern lenke)
• Ernst Asbjørn Lien; Dag Clement Johannessen; A. Aakvaag et al. (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. (ekstern lenke)
• Pål Ivar Holm; Øyvind Bleie; Per Magne Ueland et al. (2004). Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation. (ekstern lenke)
• Tuyen Hoang; Ingvild Sveinsgjerd Fenne; Carol Ann Cook et al. (2004). cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. (ekstern lenke)
• Ernst Asbjørn Lien; Bjørn Gunnar Nedrebø; Jan Erik Varhaug et al. (2000). Plasma total homocysteine levels during short-term iatrogenic hypothyreoidism. (ekstern lenke)
• Gun Birgitta Anker; Helga Refsum; Per Magne Ueland et al. (1999). Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. (ekstern lenke)
• Jennifer Gjerde; Jürgen Geisler; Steinar Lundgren et al. (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. (ekstern lenke)
• Bjørn Gunnar Nedrebø; Steinar Hustad; Jørn Schneede et al. (2003). Homocysteine and its relations to B-vitamins and smoking in graves' disease before and after treatment. (ekstern lenke)
• Andrea Decensi; Chris Robertson; Aliana Guerrieri-Gonzaga et al. (2009). Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. (ekstern lenke)
• Ernst Asbjørn Lien; Gun Birgitta Anker; Per Eystein Lønning et al. (1995). Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. (ekstern lenke)
• Bjørn G Nedrebø; Pål Ivar Holm; Sverre Uhlving et al. (2002). Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. (ekstern lenke)
• Ernst Asbjørn Lien; O. Overå (1997). Treatment of small cell lung cancer (SCLC) with high dose tamoxifen in combination with epirubicin, cyclophosphamide and oncovin. (ekstern lenke)
• Ernst Asbjørn Lien; Knut Wester; Per Eystein Lønning et al. (1991). Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. (ekstern lenke)
• Fedro Alessandro Peccatori; Giovanni Codacci-Pisanelli; Gunnar Mellgren et al. (2020). First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study. (ekstern lenke)
• Ernst Asbjørn Lien; E. Solheim; P. M. Ueland (1991). Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. (ekstern lenke)
• Gun Birgitta Anker; Asbjørn Aakvaag; Per Eystein Lønning et al. (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. (ekstern lenke)
• Ernst Asbjørn Lien; Håvard Søiland; Steinar Lundgren et al. (2013). Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. (ekstern lenke)
• Elton Richard Kisanga; Gunnar Mellgren; Ernst Asbjørn Lien (2005). Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. (ekstern lenke)
• Jennifer Fernandez Gjerde; Elton Richard Kisanga; Marianne Hauglid et al. (2005). Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. (ekstern lenke)
• N. S. A. Stuart; P. Philip; A. L. Harris et al. (1992). High dose tamoxifen as an enhancer of etoposide cytotoxicity.Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. (ekstern lenke)
• Monika Christensen; Ernst Asbjørn Lien; Simon Steinar Hustad et al. (2010). Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. (ekstern lenke)
• M. J. Milward; B. M. J. Cantwell; Ernst Asbjørn Lien et al. (1992). Intermittent high dose tamoxifen as a potential modifier of multi-drug resistance. (ekstern lenke)
• A Decensi; C Robertson; G Viale et al. (2003). A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. (ekstern lenke)
• B Bonanni; H Johansson; S Gandini et al. (2003). Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healty women. (ekstern lenke)
• Ernst Asbjørn Lien; Gun Birgitta Anker; Per Eystein Lønning et al. (1995). Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. (ekstern lenke)
• Gunnar Mellgren; Pål Ivar Holm; Ernst Asbjørn Lien et al. (2002). Tyreotoksisk periodisk paralyse - en uvanlig komplikasjon ved hypertyreose. (ekstern lenke)
• Monika Christensen; Simon E Nitter Dankel; Yngve Nordbø et al. (2011). Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. (ekstern lenke)
• RR Love; Gun Birgitta Anker; Y Yang et al. (1999). Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. (ekstern lenke)
• Elton Richard Kisanga; Jennifer Gjerde; Jan Schjøtt et al. (2003). Tamoxifen administration and metabolism in nude mice and nude rats. (ekstern lenke)
• Line Leonore Haugan Moi; Marianne Hauglid Flågeng; Jennifer Gjerde et al. (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. (ekstern lenke)
• Per Eystein Lønning; Dag Clement Johannesen; Svein Inge Helle et al. (1995). Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. (ekstern lenke)
• Ernst Asbjørn Lien; Gun Birgitta Anker; Per Magne Ueland (1995). Pharmacokinetics of tamoxifen in pre- and post-menopausal women with breast cancer. (ekstern lenke)
• Line Leonore Haugan Moi; Marianne Hauglid Flågeng; Sara Gandini et al. (2010). Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. (ekstern lenke)
• Monika Christensen; Ingvild Sveinsgjerd Fenne; Marianne Hauglid Flågeng et al. (2014). Estradiol determines the effects of PTH on ERα-dependent transcription in MC3T3-E1 cells. (ekstern lenke)
• Elton Richard Kisanga; Jennifer Gjerde; Aliana Guerrieri-gonzaga et al. (2004). Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial. (ekstern lenke)
• Ernst Asbjørn Lien; Per Eystein Lønning (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. (ekstern lenke)
• Harriet Johansson; Sara Gandini; Davide Serrano et al. (2016). A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. (ekstern lenke)
• Davide Serrano; Matteo Lazzeroni; Sara Gandini et al. (2013). A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. (ekstern lenke)
• M. J. Millward; Ernst Asbjørn Lien; A. Robinson et al. (1994). High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. (ekstern lenke)
• Ernst Asbjørn Lien; Knut Wester; Per Eystein Lønning et al. (1991). Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. (ekstern lenke)
• MH Flageng; Marianne Hauglid; Line Leonore Haugan Moi et al. (2009). Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. (ekstern lenke)
• Elton Richard Kisanga; Line Leonore Haugan Moi; Jennifer Gjerde et al. (2005). Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. (ekstern lenke)
• Per Eystein Lønning; K. Hall; A. Aakvaag et al. (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. (ekstern lenke)
• Andrea Decensi; Aliana Guerrieri-Gonzaga; Sara Gandini et al. (2011). Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. (ekstern lenke)
• Arve Ulvik; Espen Thiis Evensen; Ernst Asbjørn Lien et al. (2001). Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. (ekstern lenke)
• A Guerrieri-Gonzaga; L Baglietto; H Johansson et al. (2001). Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. (ekstern lenke)
• Ernst Asbjørn Lien; Per Eystein Lønning (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. (ekstern lenke)
• B Bonanni; D Serrano; S Gandini et al. (2009). Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia. (ekstern lenke)
• Per Eystein Lønning; Svein Inge Helle; Dag Clement Johannessen et al. (1995). Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. (ekstern lenke)
• J Geisler; Per Eystein Lønning; LE Krag et al. (2006). Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. (ekstern lenke)
• Jennifer Gjerde; Jurgen Geisler; Steinar Lundgren et al. (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. (ekstern lenke)
• Gunnar Mellgren; Bente Børud; Tuyen Thi Van Hoang et al. (2003). Characterization of receptor-interacting protein RIP140 in the regulation of SF-1 responsive target genes. (ekstern lenke)
• Ernst Asbjørn Lien; Gun Birgutta Anker; Per Eystein Lønning et al. (1997). Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. (ekstern lenke)
• Jennifer Gjerde; Sara Gandini; Aliana Guerrieri-Gonzaga et al. (2012). Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. (ekstern lenke)
• Ernst Asbjørn Lien; Gun Birgitta Anker; Per Eystein Lønning et al. (1997). Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. (ekstern lenke)
• Gun Birgitta Anker; Per Eystein Lønning; Per Magne Ueland et al. (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. (ekstern lenke)

Konferanseposter

• Jennifer Gjerde; M Hauglid; H Breilid et al. (2005). Relationship between CYP2D6 and SULT1A1 genotype and serum concentration of tamoxifen and its metabolites during steady state treatment in breast cancer patients. (ekstern lenke)
• Ernst Asbjørn Lien (2001). A comparative study of tamoxifen metabolism in immunodeficient rats and nude mice. (ekstern lenke)
• Marianne Hauglid Flågeng; Line Leonore Haugan Moi; J. Michael Dixon et al. (2009). HER-2/neu and nuclear receptor coactivators are upregulated in breast cancer tumors during estrogen deprivation. (ekstern lenke)
• Jennifer Gjerde; Jürgen Geisler; Steinar Lundgren et al. (2009). Relations between FSH, SHBG and tamoxifen metabolism during steady state tamoxifen treatment. (ekstern lenke)
• Jennifer Gjerde; Jurgen Geisler; Steinar Lundgren et al. (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. (ekstern lenke)
• Jennifer Fernandez Gjerde; Marianne Hauglid; Harald Breilid et al. (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. (ekstern lenke)
• Tuyen Hoang; Ingvild Sveinsgjerd Fenne; Ernst Asbjørn Lien et al. (2005). CHARACTERIZATION OF THE MOLECULAR MECHANISMS BY WHICH THE LEVEL OF NUCLEAR HORMONE RECEPTOR COACTIVATOR GRIP1 IS REGULATED. (ekstern lenke)
• Gunnar Mellgren; Bente Børud; Olav Erik Yri et al. (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor–1. (ekstern lenke)
• Monika Christensen; Yngve Nordbø; Jan Erik Varhaug et al. (2013). Vitamin D levels in patients with primary hyperparathyroidism; a follow-up study after parathyroidectomy. (ekstern lenke)
• Marianne Hauglid; Line Leonore Haugan Moi; Michael Dixon et al. (2008). Changes in mRNA expression levels of steroid receptor coactivators correlate with treatment response to aromatase inhibition in human breast cancer. (ekstern lenke)
• Monika Christensen; Eva Kristine Ringdal Pedersen; Yngve Nordbø et al. (2012). Systemic Inflammation in Primary Hyperparathyroidism: Influences on Plasma Vitamin B6 Levels and Interferon-γ Mediated Immune Activation. (ekstern lenke)
• Tuyen Hoang; Ingvild Sveinsgjerd Fenne; Mari Bergsvåg et al. (2009). The Role of PKA and CREB in regulation of the Steroid Receptor Coactivator GRIP1/SRC-2. (ekstern lenke)
• Marianne Hauglid Flågeng; Line Leonore Haugan Moi; Sara Gandini et al. (2010). Expression of Steroid Receptor Coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated patients. (ekstern lenke)
• BG Nedrebø; Per Magne Ueland; O Nygård et al. (2001). Plasma levels of homocysteine are changed during treatment of hyper- and hypo-thyroidism. (ekstern lenke)
• Line Leonore Haugan Moi; Elton Richard Kisanga; Jennifer Gjerde et al. (2005). Effects of low-dose tamoxifen treatment on expression of drug-metabolising enzymes in rat liver in relation to administration route. (ekstern lenke)
• Gunnar Mellgren; Bente Børud; Olav Erik Yri et al. (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1. (ekstern lenke)
• Elton Richard Kisanga; Gunnar Mellgren; Ernst Asbjørn Lien (2001). A comparative study of tamoxifen metabolism in immunodeficient nude rats and nude mice. (ekstern lenke)
• Monika Christensen; Simon E Nitter Dankel; Yngve Nordbø et al. (2011). Differential Expression of Inflammatory and Metabolic Genes in Adipose Tissue of Patients with Primary Huperparathyroidism. (ekstern lenke)
• Jennifer Fernandez Gjerde; Marianne Hauglid; Harald Breilid et al. (2007). Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients. (ekstern lenke)
• Jennifer Gjerde; Ernst Asbjørn Lien (2004). Quantification of serum tamoxifen and metabolites by liquid chromatography-tandem mass spectrometry. (ekstern lenke)
• Gunnar Mellgren; B Børud; O Yri et al. (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1. (ekstern lenke)
• Monika Christensen; Ingvild Sveinsgjerd Fenne; Marianne Hauglid Flågeng et al. (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 osteoblasts. (ekstern lenke)
• Monika Christensen; Ingvild Sveinsgjerd Fenne; Marianne Hauglid Flågeng et al. (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 Osteoblasts. (ekstern lenke)
• Siri Lunde; Thomas Helland; Janne Jonassen et al. (2018). A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway. (ekstern lenke)
• Elton Richard Kisanga; Jennifer Fernandez Gjerde; Gunnar Mellgren et al. (2002). Tamoxifen metabolism in immunocompromised rats and mice. (ekstern lenke)
• Tuyen Hoang; Ingvild Sveinsgjerd Fenne; Mona Johannessen et al. (2006). ROLES OF cAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) IN REGULATION OF GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 (GRIP1). (ekstern lenke)
• Line Leonore Haugan Moi; Elton Richard Kisanga; Jennifer Gjerde et al. (2004). Tamoxifen metabolism and induction of hepatic drug-metabolizing enzymes in nude rats. (ekstern lenke)

Konferanseforedrag

• A Gonzaga; L Baglietto; H Johansson et al. (2000). Correlation between tamoxifen elimination and biomarker recovery in a promary prevention trial. (ekstern lenke)
• Ernst Asbjørn Lien (2001). Homocysteine and thyroid function. (ekstern lenke)
• Ernst Asbjørn Lien (2004). Pharmacokinetics and pharmacodynamics of tamoxifen. (ekstern lenke)
• Ernst Asbjørn Lien; O. Overå (1997). Phase 1 and pharmacokinetic study of high dose tamoxifen combined with epirubicin, cyclophosphamide and oncovin. (ekstern lenke)
• Bjørn G Nedrebø; Sylvi Aanderud; Ottar Nygård et al. (1999). Plasma levels of homocysteine are changed during treatment of hyper- and hypothyroidism. (ekstern lenke)
• A Ulvik; Espen Thiis Evensen; Ernst Asbjørn Lien et al. (2001). Smoking, folate, and MTHFR C677T genotype as interactive determinants of adenomatous and hyperplastic polyps of colorectum. (ekstern lenke)
• Gunnar Mellgren; Bente Børud; Reidun Æsøy et al. (2002). Steroidogenesis - Role of Steroidogenic factor-1 and interacting nuclear receptor coregulators. (ekstern lenke)
• Jennifer Fernandez Gjerde; Ernst Asbjørn Lien (2005). Distribution of tamoxifen in serum and breast cancer tissue and its effects on sex hormone-binding globulin (SHBG). (ekstern lenke)

Doktorgradsavhandling

• Bjørn Gunnar Nedrebø; Ernst Asbjørn Lien (2004). Graves' disease and hypothyroidism with emphasis on treatment, homocysteine and B-vitamins. (ekstern lenke)
• Tuyen Hoang; Gunnar Mellgren; Ernst Asbjørn Lien (2007). Nuclear Receptor Coregulators Role of Protein-Protein Interactions and cAMP/PKA Signaling. (ekstern lenke)
• Ernst Asbjørn Lien (1991). Tamoxifen pharmacokinetics in breast cancer patients. Analytical methods, pharmacokinetics, tissue distribution and drug interactions. (dr.med.). (ekstern lenke)
• Elton Richard Kisanga; Ernst Asbjørn Lien (2004). Pharmacology of low-dose tamoxifen regimens in breast cancer treatment. (ekstern lenke)
• Pål Ivar Holm; Ernst Asbjørn Lien; Per Magne Ueland (2007). Betaine and its relation to homocysteine status and one-carbon metabolism in humans : analytical method and biochemical studies. (ekstern lenke)

Vitenskapelig bokkapittel

• Line Leonore Haugan Moi; Marianne Hauglid Flågeng; Simon E Nitter Dankel et al. (2011). Steroid Receptor Coactivators and Endocrine Treatment in Breast Cancer. (ekstern lenke)
• Line Leonore Haugan Moi; Marianne Hauglid Flågeng; Ingvild Sveinsgjerd Fenne et al. (2011). Steroid Receptor Coactivators and Their Expression, Regulation and Functional Role in Endocrine Responsive and Resistant Breast Cancer. (ekstern lenke)
• Jennifer Gjerde; Line Leonore Haugan Moi; Gunnar Mellgren et al. (2012). Tamoxifen metabolism and biological activity. (ekstern lenke)
• Ernst Asbjørn Lien (1994). Utprøving av dataprogrammet "Aldus Persuasion" og "Davis Transview Presenter" som hjelpemidler i forberedelse og gjennomføring av undervisning. (ekstern lenke)
• Trond Aamo; Odd Brørs; Ernst Asbjørn Lien (1998). Legemiddelanalyser og rusmiddelanalyser. (ekstern lenke)
• Per Eystein Lønning; Ernst Asbjørn Lien; K Tveter et al. (1999). Hormoner og hormonantagonister. (ekstern lenke)
• Ernst Asbjørn Lien; Knut Wester; Per Eystein Lønning et al. (1991). Tamoxifen uptake in brain tissue and brain metastases in man. (ekstern lenke)

Konferanseabstrakt

• Paal Methlie; Kristian Løvås; Ernst Asbjørn Lien et al. (2010). Grapefruit and Liquorice Increase Bioavailable Cortisol in Addison's Disease. (ekstern lenke)
• Monika Christensen; Ernst Asbjørn Lien; Bjørg Almås (2008). Vitamin D-metabolism and PTH levels show a biphasic seasonal pattern but are not correlated to osteocalcin levels in outpatients from western Norway. (ekstern lenke)
• Jennifer Gjerde; Jürgen Geisler; Steinar Lundgren et al. (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. (ekstern lenke)
• Jennifer Fernandez Gjerde; Jurgen Geisler; Steinar Lundgren et al. (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. (ekstern lenke)
• Jennifer Fernandez Gjerde; Jurgen Geisler; Steinar Lundgren et al. (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. (ekstern lenke)
• Jennifer Fernandez Gjerde; Marianne Hauglid; Harald Breilid et al. (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. (ekstern lenke)
• A Decensi; A Guerrieri-Gonzaga; S Gandini et al. (2009). Ki-67 Expression after Tamoxifen Given Preoperatively Predicts Disease Free Survival and Overall Survival in Women with Operable ER-Positive Breast Cancer. (ekstern lenke)
• Jennifer Fernandez Gjerde; Marianne Hauglid; Harald Breilid et al. (2007). Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. (ekstern lenke)
• Ernst Asbjørn Lien; Håvard Søiland; Jennifer Gjerde (2013). Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. (ekstern lenke)

Leserbrev

• Ernst Asbjørn Lien; Steinar Hustad; Bjørn Gunnar Nedrebø et al. (2001). Total plasma homocysteine in hypo- and hyperthyroidism: Covariations and causality. (ekstern lenke)
• Ernst Asbjørn Lien; Per Magne Ueland; Per Eystein Lønning (2004). Letter. (ekstern lenke)
• Håvard Søiland; Kari Britt Hagen; Jennifer Gjerde et al. (2013). Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. (ekstern lenke)

Fagartikkel

• Håvard Søiland; Emiel Janssen; Thomas Helland et al. (2022). Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin